Advertisement

FTRE

Fortrea Holdings Inc.

Healthcare · USD

Set alert

Price alert · FTRE

All alert types
21.29 USD -1.85 -7.97%
As of Oct 30, 2026 Extended hours 21.49 +0.94%
Bid
21.28 × 2
Ask
21.31 × 2
20.70 Day range 23.40
8.87 52-week range 25.88
YTD
+23.42%
1 year
+112.26%
Open
23.22
Prev close
23.14
Mkt cap
2.05B
Vol
2.87M
Avg vol
1.64M
EPS
-0.91
P/E
0.00
Div yield
0.00%
More statistics
Low
20.70
High
23.40
Forward P/E
18.35
Beta
0.00
Short ratio
4.32
Inst. own
108.42%
Dividend
0.00
Ex-div date
Earnings
Feb 25, 2027
50-d avg
20.22
200-d avg
15.67
1y target
22.63

5D chart

Chart tools
Interval
FTRE five-day price chart20.722.123.424.826.2Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
2.03B
Enterprise value
3.13B
Trailing P/E
0.00
Forward P/E
18.35
PEG ratio
0.34
Price / sales
0.76
Price / book
3.82
EPS (TTM)
-0.91
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-2.58%
Revenue (TTM)
2.67B
Revenue growth
-1.40%
Free cash flow
274.39M
Total cash
220.60M
Total debt
1.12B
Return on equity
-12.34%
Shares outstanding
96.50M
Short % of float
9.32%
50-day average
20.22
200-day average
15.67

Analyst view

Consensus: buy

Buy
Price target (mean) 22.63 +6.3% upside
Target (low)
13.50
Target (mean)
22.63
Target (high)
27.00
Ratings (0m) 13 7 buy · 4 hold · 2 sell
  • Strong buy1
  • Buy6
  • Hold4
  • Sell0
  • Strong sell2

Next earnings

Feb 25, 2027

Expected Feb 25, 2027. Consensus EPS estimate 0.21816.

Earnings history

Financials — quick view

All financials
FTRE Revenue — quarterly 691.50M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
FTRE Net income — quarterly 600.00K
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
FTRE EPS — quarterly 0.01
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

FTRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.23———
Oct 29, 2026Sep 30, 20260.21720.28+0.06+28.91%
Jul 29, 2026Jun 30, 20260.18040.23+0.05+27.49%
May 5, 2026Mar 31, 20260.030.16+0.13+433.33%
Feb 26, 2026Dec 31, 20250.160.09-0.07-43.75%
Nov 5, 2025Sep 30, 20250.160.12-0.04-25.00%

Upgrades / downgrades

FTRE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026Truist SecuritiesmainBuyBuy
Oct 30, 2026BarclaysmainOverweightOverweight
Oct 30, 2026Evercore ISI GroupmainOutperformOutperform
Oct 20, 2026UBSmainNeutralNeutral
Oct 15, 2026Deutsche BankupHoldBuy
Oct 6, 2026BarclaysupEqual-WeightOverweight

About Fortrea Holdings Inc.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
fortrea.com

News

Your note

Sign in to keep a note on FTRE — it syncs with the Stock Master app.

Insider holders

FTRE insider holders
InsiderRelationLatest transactionDateShares held
MCCONNELL JILL GChief Financial OfficerSaleJun 1, 202678,416
MORAIS MARK AChief Operating OfficerSaleSep 8, 202686,419
NEUPERT PETER MDirectorConversion of Exercise of derivative securityMay 13, 2026246,668
PESICKA EDWARD ADirectorConversion of Exercise of derivative securityJun 9, 202652,453
PIKE THOMASChief Executive OfficerSaleJan 12, 2025159,868
RAY AMRITDirectorConversion of Exercise of derivative securityJun 9, 202652,453

Institution ownership

FTRE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.61%15,799,104332.89MJun 29, 2026
Goldman Sachs Group Inc8.85%8,414,011177.28MJun 29, 2026
Sessa Capital IM, L.P.4.83%4,593,55096.79MJun 29, 2026
Vanguard Capital Management LLC4.40%4,181,55288.11MJun 29, 2026
Vanguard Portfolio Management LLC4.01%3,816,62780.42MJun 29, 2026
State Street Corporation3.98%3,784,17379.73MJun 29, 2026

Fund ownership

FTRE fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%5,659,969119.26MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%3,000,63163.22MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.63%2,497,46852.62MSep 29, 2026
Fidelity Capital Trust-Fidelity Value Fund2.41%2,290,80048.27MAug 30, 2026
LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund1.39%1,319,07927.79MJun 29, 2026
Columbia Acorn Trust-Columbia Acorn Fund1.36%1,291,98927.22MJun 29, 2026
Advertisement